International Comparison of Drug Prices with Malaysia: A Systematic Review
Malaysia Drug Price International Comparison
Vol. 17 No. 1 : 2022 (75-87)
Abstract
High drug price is a hot topic in Malaysia. In this systematic review of drug price comparison studies, we report on international comparison of drug prices with Malaysia. We systematically searched PubMed, Cochrane Library, ScienceDirect and Scopus for peer-reviewed articles. Only studies that made comparison internationally were included. Cost-effectiveness studies, budget impact analysis or costing studies were excluded. A total of 10 studies were included. Nine studies compared the price with median international reference prices (IRPs). Only one study compared the price with another country. The drug price in Malaysia for both government and public sectors was higher than IRP. This review provides the information that the drug price in Malaysia is higher than the international standard. The number of published studies in the drug pricing area is still inadequate with only one study that compares Malaysia drug price with another country. More studies are needed to improve Malaysia’s drug pricing system.
Keywords :
HEALTH EQUITY,
Health policy,
Pharmaceutical Services,
Public health,
Correspondance Address
Dr. Siew Chin Ong. Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia. Tel: +604-653 3888 Email: siewchinong@usm.my; oschin99@yahoo.com
References
Ahmad, N.S., Islahudin, F. 2018. Affordability of essential medicine prices in Malaysia’s private health sector. Patient Prefer Adherence 12: 1231-7.
Arbel, R., Greenberg, D. 2016. Rethinking cost-effectiveness in the era of zero healthcare spending growth. Int J Equity Health 15(1): 33.
Ashraf, A., Ong, S.C. 2021. Drug price control in Malaysia: a stakeholder analysis. Int J Heal Gov ahead-of-p(ahead-of-print).
Babar, Z.U., Ibrahim, M.I.M., Bukhari, N.I. 2005. Medicine Utilisation and Pricing in Malaysia: The Findings of a Household Survey. J Generic Med Bus J Generic Med Sect 3(1): 47-61.
Babar, Z.U.D., Lessing, C., Mace, C., Bissell, K. 2013. The Availability, Pricing and Affordability of Three Essential Asthma Medicines in 52 Low- and Middle-Income Countries. Pharmacoeconomics 31(11): 1063-82.
Babar, Z.D., Izham, M.I.M. 2009. Effect of privatization of the drug distribution system on drug prices in Malaysia. Public Health 123(8): 523-33.
Babar, Z.U.D., Ibrahim, M.I.M., Singh, H., Bukahri, N.I., & Creese, A. 2007. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. PLoS Med 4(3): e82.
Bloom, D., Canning, D. 2003. Health as human capital and its impact on economic performance. Geneva Pap Risk Insur - Issues Pract 28(2): 304-15.
Bloom, D.E., Canning, D., Sevilla, J. 2004. The effect of health on economic growth: a production function approach. World Dev 32(1): 1-13.
Coburn, T. 2018. Free Market, Better Medicine. Usnews.Com. https://www.usnews.com/opinion/articles/2018-02-15/rely-on-the-free-market-to-address-drug-prices-and-foster-innovation. [3 October 2021]
CodeBlue. 2019. After Pharmaniaga Loses Medicine Concession, Galen Wants Tender Agents Removed. Codeblue.Galencentre.Org. https://codeblue.galencentre.org/2019/11/01/after-pharmaniaga-loses-medicine-concession-galen-wants-tender-agents-removed [3 October 2021]
CodeBlue. 2020. Malaysia Meets WHO Target Of Doctors, Nurses For Universal Health Coverage: Minister. Codeblue.Galencentre.Org. https://codeblue.galencentre.org/2020/08/04/malaysia-has-enough-doctors-and-nurses-exceeding-who-target-minister. [3 October 2021]
Federal Constitution of Malaysia. 1957. Federal Constitution of Malaysia. https://www.jac.gov.my/spk/images/stories/10_akta/perlembagaan_persekutuan/federal_constitution.pdf. [3 October 2021]
Hamzah, N., Perera, P.N., Rannan-Eliya, R.P. 2020. How well does Malaysia achieve value for money in public sector purchasing of medicines? Evidence from medicines procurement prices from 2010 to 2014. BMC Health Serv Res 20(1): 509.
Hassali, M.A., Shafie, A.A., Babar, Z.U.D., Khan, T.M. 2012. A study comparing the retail drug prices between Northern Malaysia and Australia. J Pharm Heal Serv Res 3(2): 103-7.
International Pharmaceutical Federation. 2015. Basel Statements : The future of hospital pharmacy practice. Basel Statements. https://www.fip.org/basel-statements. [3 October 2021].
Malaysia Competition Commission. 2017. Market review on priority sector under Competition Act 2010 pharmaceutical sector. Malaysia Competition Commission (MyCC). http://www.mycc.gov.my/sites/default/files//media-review/Market Review on Pharmaceutical Sector.pdf. [3 October 2021].
Mcintyre, D., Meheus, F., Røttingen, J.A. 2017. What level of domestic government health expenditure should we aspire to for universal health coverage? Heal Econ Policy Law 12(2): 125-37.
Ministry of Health Malaysia. 2019. Malaysia National Health Accounts: Health Expenditure Report 1997-2017. In Ministry of Health Malaysia. https://www.moh.gov.my/moh/resources/Penerbitan/Penerbitan Utama/MNHA/Laporan_MNHA_Health_Expenditure_Report_1997-2017_03122019.pdf. [3 October 2021].
Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G. 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339: b2535–b2535.
Mwachofi, A., Al-Assaf, A.F. 2011. Health care market deviations from the ideal market. Sultan Qaboos Univ Med J 11(3): 328-37.
Ouzzani, M., Hammady, H., Fedorowicz, Z., Elmagarmid, A. 2016. Rayyan—a web and mobile app for systematic reviews. Syst Rev 5(1): 210.
Pharmaceutical Services Division. 2017. Pharmacy Programme Annual Report 2016. https://www.pharmacy.gov.my/v2/sites/default/files//document-upload/laporan-tahunan-2016-program-farmasi.pdf. [3 October 2021].
Pollack, A. 2015, September 20. Drug Goes From $13.50 a Tablet to $750, Overnight. New York Times. https://www.nytimes.com/2015/09/21/business/a-huge-overnight-increase-in-a-drugs-price-raises-protests.html. [3 October 2021].
Rémuzat, C., Urbinati, D., Mzoughi, O., El Hammi, E., Belgaied, W., Toumi, M. 2015. Overview of external reference pricing systems in Europe. J Mark Access Heal Policy 3(1): 27675.
Roza, S., Junainah, S., Izzuna, M.M.G., Ku Nurhasni, K.A.R., Yusof, M.A.M., Noormah, M.D., Syful Azlie, M.F., Sit Wai, L. 2019. Health Technology Assessment in Malaysia: Past, Present, and Future. Int J Technol Assess Health Care 35(6): 446-51.
Sullivan, S.D., Mauskopf, J.A., Augustovski, F., Jaime Caro, J., Lee, K.M., Minchin, M., Orlewska, E., Penna, P., Rodriguez Barrios, J.M., Shau, W.Y. 2014. Budget Impact Analysis-Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Heal 17(1): 5-14.
Wong, S.L., Ibrahim, S., Abdul Kadir, N., Mohd Salleh, S. 2019. Access and affordability of medicines in Malaysia: need for a national pricing policy. Appl Health Econ Health Policy 17(5) 641-54.
Wong, S.L., Ibrahim, S., Kadir, N.A., & Salleh, S.M. 2018. PCN25 - Evaluating availability, prices and affordability: case study of selected oncology and innovator medicines in Malaysia. Value Heal 21: S12-13.
World Health Organization. 2016. Sustainable Development Goals (SDGs). https://www.who.int/health-topics/sustainable-development-goals [3 October 2021].
World Health Organization. 2017. Financial protection in the South-East Asia region: determinants and policy implications. https://www.who.int/health_financing/events/who_searo_uhc_day_report_web.pdf. [3 October 2021].
World Health Organization. 2020. Global spending on health: Weathering the storm. https://www.who.int/publications/i/item/9789240017788. [3 October 2021].
World Health Organization. 2021. World Health Organization Global Health Expenditure database. https://data.worldbank.org/indicator/SH.XPD.CHEX.GD.ZS?locations=MY. [3 October 2021].
You, H.W., Tajuddin, N.S.A., Anwar, Y.A.S. 2019. Measuring availability, prices and affordability of ischaemic heart disease medicines in Bangi, Selangor, Malaysia. Malays J Med Sci 26(5): 113-21.
